GlassScriptPhysician profile
Darin H Poulsen
NPI 1659942464
$1,909.34
in general payments reported to CMS, 2019-2025
27 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $286 · 2023: $1,121 · 2024: $333 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,239 · Education: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,239.02 |
| Education | $384.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $284.29 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $185.58 | 2022-2024 | Tecvayli, Darzalex, Carvykti |
| Novartis Pharmaceuticals Corporation | $174.34 | 2022-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $157.53 | 2023 | Imbruvica, Epkinly |
| Pfizer INC. | $131.70 | 2023-2025 | |
| Lilly USA, LLC | $126.06 | 2022-2023 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $112.61 | 2023 | Padcev |
| Astrazeneca Pharmaceuticals LP | $95.87 | 2023-2025 | Lynparza |
| Sanofi-Aventis U.S. LLC | $89.99 | 2024 | |
| Amgen INC. | $56.90 | 2022-2023 | Kyprolis, Lumakras |
| Emd Serono, INC. | $54.70 | 2023-2024 | Bavencio |
| Gilead Sciences, INC. | $47.26 | 2022-2023 | Trodelvy |
| Abbvie INC. | $45.50 | 2022-2024 | |
| Beigene USA, INC. | $37.12 | 2022-2023 | Brukinsa |
| Myriad Genetic Laboratories, INC. | $32.03 | 2022-2023 | Precisetumor |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $29.84 | 2023-2024 | Reblozyl, Pomalyst |
| Genentech USA, INC. | $28.59 | 2024 | Avastin, Tecentriq, Rozlytrek |
| Regeneron Healthcare Solutions, INC. | $27.71 | 2022 | |
| Mirati Therapeutics, INC. | $26.26 | 2023 | Krazati |
| Stemline Therapeutics INC. | $25.81 | 2025 | Elzonris |
| Glaxosmithkline, LLC. | $24.65 | 2023 | Zejula |
| Eisai INC. | $22.54 | 2024 | |
| Genzyme Corporation | $20.18 | 2024 | |
| Pharmacosmos Therapeutics INC. | $19.61 | 2023 | Monoferric |
| Array Biopharma INC | $19.45 | 2023 | Lorbrena, Braftovi |
| Sobi, INC | $17.89 | 2023 | |
| Adc Therapeutics America, INC. | $15.33 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darin Poulsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.